Parkinson’s disease, affecting over a million individuals in the United States alone and millions more worldwide, manifests with symptoms ranging from tremors and motor impairments to cognitive decline, sleep disturbances, and motivational deficits. Traditionally, therapies have targeted symptomatic relief, typically through life-long pharmacological regimens or deep brain stimulation (DBS), which employs invasive electrode implantation. However, while alleviating some symptoms, these approaches fall short of halting or reversing disease progression. The new study shifts the paradigm by pinpointing the SCAN as the neurological epicenter and offering innovative, non-invasive therapeutic options.

The SCAN, first described by researchers at Washington University School of Medicine in 2023, resides within the motor cortex — the brain’s command center for voluntary movement. This network is crucial for transforming cognitive action plans into physical movements while simultaneously integrating sensory feedback to refine execution. Given the complexity and multifaceted symptoms of Parkinson’s, researchers hypothesized that SCAN dysfunction might explain the broader symptom spectrum beyond motor control, encompassing cognitive and autonomic functions.

To test this hypothesis, the research consortium led by Changping Laboratory in China collaborated closely with Washington University in St. Louis and other institutions. They amassed brain imaging data from more than 800 participants, spanning different therapeutic modalities including DBS, transcranial magnetic stimulation (TMS), focused ultrasound, and pharmacological treatments, alongside healthy controls and individuals with other movement disorders. This large dataset enabled a comprehensive network analysis that revealed Parkinson’s-related pathology as characterized by an aberrant hyperconnectivity between SCAN and the brain’s subcortical regions while other neurodegenerative disorders did not demonstrate this pattern.

The hyperconnectivity between SCAN and subcortical structures — areas responsible for emotion, memory, and motor regulation — disrupts the normal orchestration of motor and cognitive functions that Parkinson’s patients suffer. This abnormal neural wiring does not only cause the classic motor impairments traditionally linked to Parkinson’s but also impairs associated cognitive processes and bodily functions, broadening the disease’s impact beyond prior conceptions. This insight reconceptualizes Parkinson’s as a disorder of broader somato-cognitive network dysfunction rather than isolated basal ganglia pathology.

Building on these insights, researchers devised a highly precise neuromodulation strategy leveraging advanced TMS technology. This non-invasive technique applies targeted magnetic pulses across the scalp to modulate neuronal activity with millimeter spatial accuracy. In clinical trials, transcranial magnetic stimulation focused specifically on SCAN regions more than doubled symptom improvement compared to stimulation of adjacent brain areas not directly associated with the network. Over two weeks, 56% of patients who received SCAN-targeted TMS exhibited meaningful clinical improvement, a compelling contrast to the 22% response rate in the control group.

The implications of these findings are profound; they demonstrate for the first time that precision neuromodulation of a finely defined network can markedly enhance therapeutic efficacy in Parkinson’s treatment while avoiding the risks of surgical interventions like DBS. Moreover, because TMS is non-invasive, it opens avenues for earlier intervention in the disease course, potentially slowing or even reversing progression rather than solely managing symptoms in advanced stages.

This discovery is just the beginning. Researchers underscore the need for further basic and translational studies to elucidate how distinct SCAN components relate to specific Parkinsonian symptoms. Such dissected understanding will pave the way for even more specialized and personalized interventions that can address the heterogeneous clinical presentations of Parkinson’s disease. The team is actively planning additional clinical trials employing other cutting-edge neuromodulation methods, such as low-intensity focused ultrasound, which uses acoustic energy to remotely and non-invasively modulate brain circuitry.

Further advancing clinical possibilities, co-author Dr. Nico Dosenbach, a co-founder of Turing Medical — a startup spun out of Washington University — is developing surface electrode strip technologies for targeted neuromodulation of SCAN regions to improve gait dysfunction in Parkinson’s. Partnering novel technology development with translational clinical research reflects a paradigm of precision medicine aiming for high-impact, scalable, and patient-friendly therapies.

This landmark study exemplifies how the convergence of multi-institutional collaboration, advanced neuroimaging, network neuroscience, and innovative therapeutic technologies can break new ground in understanding and treating complex neurological diseases. By reframing Parkinson’s disease as a disorder of the somato-cognitive action network, the researchers have opened an exciting new chapter that promises to transform future management strategies and offer renewed hope for millions worldwide.

Subject of Research: People

Article Title: Parkinson’s disease as a somato-cognitive action network disorder

News Publication Date: 4-Feb-2026

Web References: DOI: 10.1038/s41586-025-10059-1

References:
Ren J, Zhang W, Dahmani L, Gordon EM, Li S, Zhou Y, Long Y, Huang J, Zhu Y, Guo N, Jiang C, Zhang F, Bai Y, Wei W, Wu Y, Bush A, Vissani M, Wei L, Oehrn CR, Morrison MA, Zhu Y, Zhang C, Hu Q, Yin Y, Cui W, Fu X, Zhang P, Wang W, Ji GJ, Wang K, Wang Z, Kimberley T, Little S, Starr PA, Richardson RM, Li L, Wang M, Wang D, Dosenbach NUF, Liu H. Parkinson’s disease as a somato-cognitive action network disorder. Nature. Feb. 4, 2026.

Image Credits: Sara Moser/WashU Medicine

Keywords: Parkinson’s disease, Neurological disorders, Neurology, Brain stimulation

Hemifacial spasm, a debilitating disorder characterized by involuntary, repetitive contractions of muscles on one side of the face, has long posed therapeutic challenges. Traditional treatments range from invasive surgical interventions to pharmacological approaches, each with significant limitations, side effects, or variable efficacy. The newly developed wearable system, designed by Qu, Wan, Zhao, and colleagues, leverages the body’s own biomechanical signals through triboelectric sensing to create a feedback loop that immediately counteracts spasmodic activity, providing a non-invasive, user-friendly alternative with the potential for substantial quality-of-life improvements.

At the heart of this technology is the triboelectric sensor, which capitalizes on the triboelectric effect — a phenomenon where certain materials become electrically charged after coming into contact and then separating from another material. This sensor is adept at capturing minute mechanical vibrations and muscle activities intrinsic to hemifacial spasms. Unlike traditional electromyography (EMG), which often requires complex signal processing and external amplification, triboelectric sensing offers a high signal-to-noise ratio with enhanced sensitivity to subtle muscle movements, enabling real-time and accurate detection of spasms.

The closed-loop aspect of the system is what truly elevates its therapeutic potential. Once spasmodic activity is detected by the triboelectric sensor, the device instantaneously delivers targeted neurostimulation to the affected muscles. This responsive stimulation inhibits the aberrant neuromuscular signals responsible for the spasms, effectively disrupting the pathological feedback loop. Such real-time intervention not only mitigates the immediate manifestations of spasms but can potentially retrain the nervous system over time, reducing their overall frequency and intensity.

Implementing this advanced closed-loop mechanism within a wearable form factor required overcoming substantial engineering hurdles. The research team employed miniaturized, flexible electronics that conform seamlessly to the facial contours, ensuring user comfort and unobtrusiveness during daily use. Battery life optimization, wireless communication protocols, and integration of low-latency processing units were meticulously engineered to support continuous monitoring and therapeutic delivery throughout daily activities, reflecting a patient-centric design philosophy.

One of the pivotal challenges addressed by the researchers was differentiating pathological spasms from normal facial expressions and movements. The system incorporates sophisticated algorithms capable of discriminating between involuntary spasms and voluntary muscle activity, reducing false positives and ensuring that neurostimulation is delivered only when truly necessary. This selective engagement minimizes unnecessary stimulation, limits adverse effects, and enhances user acceptance by preserving natural facial expressivity.

Clinical experimentation demonstrated the device’s efficacy in both controlled and real-world environments. Patients reported significant alleviation of hemifacial spasm symptoms, enhanced comfort, and increased confidence in social interactions owing to the reduction in visible spasms. These outcomes highlight the system’s potential not merely as a symptomatic treatment but as a transformative tool in managing a chronic, often stigmatizing condition.

Beyond its immediate clinical implications, this closed-loop wearable device embodies a model for future next-generation neuromodulation therapies. The integration of smart sensing with adaptive stimulation underscores a broader paradigm shift in neural interfacing technologies — one that moves away from open-loop, preprogrammed interventions toward dynamic, physiology-driven therapeutic systems. Such advancements promise to unlock new possibilities across a spectrum of neurological and neuromuscular disorders where conventional treatments fall short.

Researchers also emphasize the scalability and adaptability of the triboelectric sensing platform. While tailored for hemifacial spasms in this iteration, the underlying sensor technology and closed-loop framework could be calibrated for other conditions characterized by abnormal muscle activity, including dystonia, essential tremor, or even rehabilitation after stroke. This versatility positions the device as a cornerstone innovation with a wide therapeutic horizon.

From a materials science perspective, the study highlights remarkable progress in the development of durable, biocompatible triboelectric materials that maintain performance over prolonged usage without causing skin irritation or allergic reactions. Such properties are critical for devices intended for continuous wear, as comfort and safety directly impact patient compliance and overall effectiveness. The engineers behind the system achieved an optimal balance between mechanical flexibility and electrical sensitivity, ensuring robust and reliable operation.

The integration of machine learning algorithms within the closed-loop system further enhances its adaptability. Through continuous monitoring and data collection, the device personalizes stimulation parameters for individual users, learning from their unique muscle activity patterns and optimizing therapeutic interventions accordingly. This intelligent customization represents a leap toward truly personalized medicine in the realm of wearable neurotechnology.

Deployment of this wearable neurostimulation system also opens new avenues for remote monitoring and telemedicine. The wireless connectivity embedded within the device allows clinicians to track patient progress, adjust stimulation protocols, and intervene when necessary — all without frequent in-person visits. This connectivity is especially beneficial for patients in remote or underserved areas, expanding access to high-quality neurological care.

In conclusion, the closed-loop wearable neurostimulation system with triboelectric sensing introduced by Qu and colleagues signifies a monumental advance in both neuroengineering and clinical therapeutics. By seamlessly combining real-time sensing with adaptive stimulation in a patient-friendly, wearable format, this technology not only addresses the pressing needs of hemifacial spasm sufferers but also lays the groundwork for a new generation of intelligent neuromodulation platforms. As this paradigm evolves, it is poised to revolutionize the management of neurological disorders and enhance the quality of life for millions worldwide.

This research, published in Nature Communications, underscores the fruitful intersection of interdisciplinary collaboration, harnessing insights from neuroscience, materials science, electrical engineering, and clinical medicine. The team’s work exemplifies how innovative sensor technologies paired with closed-loop systems can transform therapeutic landscapes, inspiring further exploration and development in wearable neurotechnology. Future studies will undoubtedly expand on these promising findings, aiming to refine the device, validate long-term outcomes, and broaden clinical applicability.

In the broader scientific context, the advent of such sophisticated wearable neuromodulation devices aligns with contemporary trends emphasizing minimally invasive, patient-specific therapy modes. It resonates deeply with the ongoing ambition to develop smart technologies that not only treat but anticipate medical conditions, thereby delivering proactive care and prevention. The triboelectric-based closed-loop system presented here stands as a testament to this vision, heralding a new era in neurological health management.

Subject of Research: Wearable neurostimulation device for treatment of hemifacial spasms using triboelectric sensing.

Article Title: Closed-loop wearable neurostimulation system with triboelectric sensing to alleviate hemifacial spasms.

Article References:
Qu, X., Wan, J., Zhao, H. et al. Closed-loop wearable neurostimulation system with triboelectric sensing to alleviate hemifacial spasms. Nat Commun 16, 11148 (2025). https://doi.org/10.1038/s41467-025-67121-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-67121-9

Cody Krebs, a 32-year-old who endured a severe spinal cord injury following a motor vehicle accident in 2022, embodies the transformative potential of this innovation. Prior to receiving the implant, Krebs grappled daily with dramatic fluctuations in his blood pressure, oscillating between sudden dangerous drops that risked inducing loss of consciousness and extreme spikes that heightened his likelihood of heart attack or stroke. His lived experience highlights a critical yet under-addressed facet of SCI: autonomic dysregulation of cardiovascular function, which has often been overshadowed by efforts focusing predominantly on restoring motor function.

The research, spearheaded by multidisciplinary teams from the University of Calgary, École Polytechnique Fédérale de Lausanne (EPFL), the University of Lausanne (UNIL) in Switzerland, and medical centers in the Netherlands, was published simultaneously in the revered journals Nature and Nature Medicine. These landmark studies delineate not only the physiological challenges faced by SCI patients but also reveal comprehensive neuronal mapping of the spinal cord circuits responsible for autonomic dysreflexia—a potentially fatal condition characterized by unchecked, life-threatening elevations in blood pressure.

Central to this breakthrough is the development of an implantable spinal neurostimulation system composed of specialized electrode arrays strategically positioned along the spinal cord. These electrodes interface with a custom-designed pulse generator akin to a cardiac pacemaker, delivering targeted electrical impulses that modulate the complex neuronal architecture controlling blood pressure. Importantly, the stimulation parameters are individually calibrated, allowing personalized therapy that adapts dynamically to each patient’s specific autonomic profile.

This implantable system leverages recent advances in neuroscience and biomedical engineering to achieve real-time neuromodulation. By finely tuning the patterned electrical stimuli, the device effectively competes with pathological sympathetic overactivity that drives blood pressure aberrations after SCI. In clinical trials spanning Canada, Switzerland, and the Netherlands, participants experienced rapid normalization of blood pressure within minutes of activating the device, underscoring the therapy’s efficacy and immediate impact.

Aaron Phillips, PhD, director of the RESTORE Network and associate professor at the Cumming School of Medicine at the University of Calgary, emphasized the translational significance of these findings. He noted that this research elegantly bridges the foundational science of neuronal circuit mapping with practical clinical application—facilitating an unprecedented acceleration from laboratory discovery to therapeutic implementation. The studies jointly demonstrate not only the severity of chronic hypotension and hypertensive spikes post-SCI but also validate the neuromodulation approach across diverse healthcare settings and protocols internationally.

Long-term, the chronic instability of blood pressure in SCI patients can exact a profound toll. Persistent low blood pressure leads to chronic fatigue, diminished cognitive acuity, and heightened fainting risk, while extreme hypertensive episodes precipitate strokes and myocardial infarctions. By deploying this novel neuromodulation therapy, researchers have shown durable regulation that prevents these deleterious cardiovascular events, thus offering a paradigm shift in managing autonomic complications of SCI beyond symptomatic treatment.

The detailed neuronal architecture characterized in the Nature publication reveals the specific spinal networks orchestrating autonomic dysreflexia. This understanding enables precise stimulation strategies that modulate rather than suppress neuronal activity, preserving physiological adaptability while preventing dangerous blood pressure surges. Grégoire Courtine, PhD, director of the NeuroRestore Center and EPFL professor, describes this approach as a sophisticated interplay between device-guided electrical input and the host’s neurophysiology to restore homeostasis.

Clinicians employing the implant observed rapid improvements extending beyond blood pressure stabilization. Patients reported enhanced mental clarity, reduced brain fog, increased energy levels, and better tolerance to post-meal blood pressure dips. Neurosurgeon Ilse van Nes, MD, PhD, who facilitated implant surgeries and follow-ups at Sint Maartenskliniek Rehabilitation Center in Nijmegen, highlighted the system’s ease of use in everyday settings, indicating strong potential for widespread clinical adoption.

Neurosurgeon Jocelyne Bloch of Lausanne University Hospital noted the international clinical deployment’s success as a pivotal milestone toward global accessibility. The implant’s surgical procedure demonstrates safety and reproducibility across different health systems—a critical consideration for scalability. Furthermore, Dr. Fady Girgis from the Foothills Medical Centre affirmed the robust safety profile of the implantable device, given its established use in pain management, enabling a seamless transition to this novel indication for blood pressure control.

Patient testimonials affirm the profound personal impact of this therapy. Krebs expressed renewed confidence and gratitude, emphasizing his regained ability to control blood pressure fluctuations, experience heightened mental functioning, and reduce risk of harmful spikes. These qualitative benefits reflect meaningful improvements in daily living, psychosocial well-being, and long-term health prospects.

The implantable neurostimulation platform originates from the neurotechnology company ONWARD Medical, which recently received FDA approval to launch a pivotal trial expanding participation to approximately 20 leading neurorehabilitation and neurosurgical centers across North America and Europe. This next phase aims to validate the therapy’s efficacy and safety in broader, more diverse patient populations—potentially establishing a new standard of care for autonomic dysregulation in SCI.

This novel neurostimulation technology exemplifies the synergy of interdisciplinary innovation, integrating neuroscientific discovery, engineering prowess, and clinical expertise. It highlights the remarkable potential to harness targeted electrical modulation for restoring complex autonomic functions lost to spinal cord injury, addressing a critical unmet medical need that affects millions worldwide. As this therapy advances through clinical phases, it holds promise not only for SCI patients but also for broader applications in treating dysautonomic conditions characterized by vascular instability.

In conclusion, the development and clinical translation of this neurostimulation implant represent a transformative leap forward in managing spinal cord injury’s autonomic sequelae. By illuminating the intricate spinal cord circuitry behind blood pressure dysregulation and harnessing it through an adaptable, patient-specific implant, the researchers have charted new territory in personalized neuromodulation therapies. This innovation stands to dramatically improve functional independence, reduce cardiovascular morbidity, and enhance quality of life for people navigating the challenges of a life-altering injury.

Subject of Research: People

Article Title: A neuronal architecture underlying autonomic dysreflexia

News Publication Date: 17-Sep-2025

Web References: http://dx.doi.org/10.1038/s41586-025-09487-w

Image Credits: University of Calgary

Keywords: Blood pressure, Medical technology, Medical treatments, Nerve injuries, Spinal cord injuries